Revenue

A one-time gain gave the micro-cap a profitable quarter, but rising costs and reliance on a single large asset raise questions about its long-term stability.

A new ultra-low fee for large deals challenges traditional brokers and signals a digital revolution in the multi-billion dollar secondary market.

A new study reveals a significant financial confidence gap between military and civilian households, highlighting the impact of unique benefits and coaching.

Investors eye Alaska Air Group's Q1 results for insights on the Hawaiian Airlines integration, rising fuel costs, and shifting travel demand.

INLIF LIMITED's 1-for-16 reverse stock split aims to secure its Nasdaq listing, but is it a strategic fix or a sign of deeper financial trouble?

A landmark case could strip healthcare giants of a key legal defense, holding them accountable for allegedly deceiving seniors into for-profit Medicare plans.

Onfolio Holdings reports 36% revenue growth and positive EBITDA, but a wider net loss and auditor warnings reveal a high-stakes strategy for 2026.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

A scathing new report reveals systemic failures in federal Indigenous procurement, validating long-standing calls to end 'gilding' and phantom ventures.

With a seasoned team and $253 million in fresh capital, Inflection Point's new SPAC signals strong investor confidence in a disciplined market.

A new FDA-cleared chair offers a non-invasive solution for bladder leakage, but how does the technology stack up in a rapidly growing market?

The luxury brand missed Q4 estimates, citing market challenges, but CEO Gary Friedman laid out a bold, multi-year path for global expansion and growth.

JFrog's new plugin for the Cursor AI editor embeds software supply chain security directly into developer workflows, aiming to tame the risks of autonomous coding.

With Stacy Walton as its first CCO, Longitude Rx signals a major push to disrupt specialty pharmacy and empower health systems against market headwinds.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

Banking tech leader nCino posts record FY2026 results, fueling a major stock buyback and signaling deep confidence in its AI-driven global strategy.

Concord's new SVP of Sales, Andrew Coffey, brings deep operational experience, signaling a strategic shift to prioritize execution in a competitive market.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

The carbon-tech firm slashes losses and touts a key SAF partnership, but dwindling cash reserves raise questions about its path to sustainable growth.

Investors in distressed Ravelin Properties REIT are forming a group to scrutinize a $1.1B rescue deal, signaling a potential battle over its fairness.